BeiGene, Ltd. (ONC) shares ended the last trading session 3.2% higher at $244.20. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This ...

Yet oncology products have a greater likelihood than other therapy areas to fail at Phase III (see graph) – well after the branding process has already begun and market expectations are somewhat ...

It’s clear the growth rate for oncology products is slowing. Figure 1 Global Oncology Sales and Growth Considering this moderating growth, IMS conducted an Oncology Launch Excellence Study to ...

The company is set to launch a lineup of specialty medications and generic oncology products, with plans to introduce 45 to 50 new generic products throughout the year. Camber is reflecting on its ...

Gilead Sciences reported strong fourth-quarter earnings with significant growth in its HIV and oncology segments.

Elevation Oncology , Inc. (NASDAQ:ELEV), a biotechnology firm specializing in biological products with a current market capitalization of $41 million, announced the upcoming departure of its Chief ...

“We aim to develop BioNTech into a global immunotherapy powerhouse with the potential to improve the standard of care with innovative oncology products and prophylactic vaccines against ...

Revenue growth was fueled by oncology products, particularly ENHERTU, which retained leading market shares in the US, Europe, Japan, and ASCA markets for multiple indications. European sales ...